# SELLING PROCESS ADOPTED BY THE PHARMACEUTICAL COMPANIES.

\*. Madheen Ahmed . A. Research Scholar, Department of Commerce, Chikkanna Govt Arts College, Tiruppur.

\*\* Dr. GB.Karthikeyan, Head - Department of Commerce (IB), Govt arts College,

Coimbatore.

## Abstract

Pharmaceutical Companies are responsible for the current shift in the marketing strategies. Leading companies are using high-end development and not adaptive development, new innovation-based companies are going places and companies not doing innovation in products and processes are finding difficult, to compete with organizations adapting innovation. The pharmaceutical industry is highly complex. The technologies leading to drug Discovery and development are at the peak of human knowledge. The huge size of the companies and the complexities of their processes and technologies results in many organizational and management challenges. The development and management of the distribution system is highly costly. My study analyse the processes and outcomes of pharmaceutical companies. This article will present the selling process adopted by pharmaceutical companies.

Key words: Marketing strategies, Selling process, pharmaceutical company,

# Introduction

India is blessed with huge population in the world, and the effect of illness and health deterioration too. in order to supplement for the huge population base, many pharmaceutical companies are landed in India and involved in the production of drugs. The production from india is supplied up to 50 percent for the global demand, and 50 percent to USA and UK. further the Indian pharmaceutical sector was valued for 33 billion America dollars in the year 2017. To add up the pharma companies strive its level maximum to push and popular their products like other sectors do. The very complicated problem in pharma marketing is that the end consumer cannot be taken as the final recipient and the recipient have to be reached through physician. The major marketing strategies includes the product, price , promotion and place.

## Need for the study

The study is intended to know the marketing strategies of the company. Since, the company growth depends upon their sales conditions only. The study mainly deals with the marketing activities of the company. The main objective of the study is to know how the company performs its marketing activities for the attainment of its goals. The study covers the various selling process adopted by the pharmaceutical companies.

### **Review of literature**

- Jaya Prakash Pradhan (2006). It is found that strategic government policies were the main factors that transformed the status of the Indian pharmaceutical industry from a mere importer and distributor of drugs and pharmaceuticals to an innovation driven cost effective producer of quality drugs. India emerged as one of the fast growing pharmaceutical industry in the world with growing trade surpluses and exports. However, there are certain limitations that the government policies need to address, like low productivity and R&D intensity. A host of competitive strategies, like Greenfield direct investment, overseas acquisitions, strategic alliances and contract manufacturing have emerged as favorites to Indian pharmaceutical firms recently
- Elizabeth Murray et al. (2007) compares and contrasts the main quality standards in the highly regulated pharmaceutical industry with specific focus on Good Clinical Practice (GCP), the standard for designing, conducting, recording and reporting clinical trials involving human participants. Comparison is made to ISO quality standards, which can be applied to all industries and types of organisation. The study is then narrowed to that of contract research organisations (CROs) involved in the conduct of clinical trials. The paper concludes that the ISO 9000 series of quality standards can act as a company-wide framework for quality management within such organisations by helping to direct quality efforts on a longterm basis without any loss of compliance. This study is valuable because comparative analysis in this domain is uncommon.
- Chris Cousins (2009) in his research publication describes how the patient physician relationship has been compromised by pharmaceutical giants. At one time, a doctor's primary concern was the health of the patient. During this time, no incentives existed for doctors to prescribe certain medications and the prescription process was adequately assessed by the physician in order to deter potential side effects. By influencing medical education, companies control the distribution channel for their product. Using unethical; marketing techniques, including misleading direct-to-consumer marketing and condition branding, the

pharmaceutical industry creates and maintains a market for their product. The combination of these two influences demonstrates how pharmaceutical companies exploit physicians and patients alike in order to maintain themselves as a dominant force in the American economy.

### **Objective of the study**

To analyse the selling process adopted by pharmaceutical companies

### Sample design and study area

For the purpose of the study, a survey instrument was prepared for the medical representative who were employed in the districts of Coimbatore, erode, and Tiruppur in Tamilnadu state. All these representatives were employed in the pharmaceutical companies of Pfizer, Glaxo smith kline, Sanofi Aventis, MSD, Abbott laboratories. A total of 350 medical representatives were asked to fill the questionnaire of which only 306 were properly filled in and the rest were duly rejected for not filling. The total respondents after rejections 199 medical representatives who were working for Pfizer of which 72 of them from Coimbatore, 27 from erode, 10 from Tirupur. A 90 representative of Glaxo Smithkline have fallen to 44 from Coimbatore, 38 from erode, 8 from Tirupur. 57 medical representatives who work for Sanofi Aventis has been classified in to 31 from Coimbatore, 17 from erode, and 9 were accounted to Tiruppur. A 26 representative who work for MSD has been classified in to 18 from Coimbatore, 8 from erode, and 5 from Tirupur. An 24 representatives who base 13 from Coimbatore, 6 from erode, and 5 from Tiruppur.

Demographic pro	file of the respondents	Frequency	Percent
	Coimbatore	178	58.2
District in which omnloved	Erode	96	31.4
District in which employed	Tiruppur	32	10.5
Educational qualification	UG	141	46.1
Educational quantication	PG	165	53.9
	25-35	128	41.8
Age group	36-45	111	36.3
	46-55	67	21.9
	0-5	130	42.5
Experience	6-10	118	38.6
Ехрепенсе	11-15	29	9.5
	Coimbatore         178           which employed         Erode         96           Tiruppur         32           nal qualification         UG         141           PG         165           25-35         128           36-45         111           46-55         67           0-5         130           6-10         118	9.5	

Source: Computed from Primary Data

Panel 1explains the district employed by the respondents, it can be inferred that 58.2 per cent of them employed in Coimbatore district, 31.4 per cent of them employed in erode district and 10.5 per cent of them were employed in tiruppur district.

Panel 2 represents the educational qualification of the respondents, 53.9 per cent have completed post-graduation and 46.1 per cent of them have completed under graduation.

Panel 3 highlights the age group of the respondents, 41.8 percent of the respondents were in the age group of 25 - 35 years, 36.3 percent of the respondents were in the the age group of 36 - 45 years and a 21.9 percent of the respondents were in the age group of 46 - 55 years.

Panel 4 illustrate the experience of the respondents, 0 - 5 years of experience, 38.6 per cent of them had 6 - 10 years of experience, 19 per cent of them have 11 - 15 years of experience and 16 - 20 years of experience by sharing 9.5 per cent respectively.

S.No.		Frequency	Percent
	Pharma	145	47.4
Selling category	Vaccines	84	27.5
	Healthcare	77	25.2
	Pfizer	109	35.6
	Glaxo smith kline	90	29.4
<b>Type of Company</b>	Sanofi Aventis	57	18.6
	MSD	26	8.5
	Abbott Laboratories	24	7.8
	Demographic	145	47.4
Market segmentation	Geographic	81	26.5
	Behavioural	80	26.1
	Concentrate on segment	28	9.2
	Concentrate on brand	42	13.7
Marketing strategy	Concentrate on generic	28	9.2
	Concentrate on segment and brand	106	34.6
	Concentrate on segment and generic	102	33.3
	Product	151	49.3
Attributa inaraasa sala	Process	39	12.7
Au nuite increase sale	Packaging	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	10.1
Selling categoryVaccines84Healthcare77Healthcare77Pfizer109Glaxo smith kline90Sanofi Aventis57MSD26Abbott Laboratories24Demographic145Geographic81Behavioural80Concentrate on segment28Concentrate on brand42Concentrate on segment and brand106Concentrate on segment and generic102Product151Process39Packaging31	27.8		

Table 2: Marketing strategies adopted.

Source: Computed from Primary Data

Panel 1explains the selling category,47.4 per cent respondents were involved in marketing of pharma products, 27.5 per cent respondents were involved in vaccines and 25.2 per cent respondents were involved in selling of healthcare products.

Panel 2 highlights the type of company, 35.9 per cent of the respondents are working for Pfizer, 29.4 per cent of them are working for Glaxo smith kline, 18.6 per cent of them are

working for Sanofi Aventis, 8.5 per cent of them are working for MSD and 7.8 per cent of them are working for Abbott Laboratories.

Panel 3illustrate market segmentation, 47.4 per cent of the pharmaceutical companies adopt demographic segmentation, 26.5 per cent of the pharmaceutical companies adopt geographic segmentation and 26.1 per cent of the pharmaceutical companies adopt Behavioural segmentation.

Panel 4details marketing strategy, 34.6 per cent of the pharma companies focus on both segment and branded strategies, 33.3 per cent of them focus on both segment and generic strategies, 13.7 per cent of them concentrate on brand strategies, 18.4 per cent of them focus on both segment and generic strategies, sharing 9.2 per cent respectively.

Panel 5bringsthe attribute increase sale, 49.3 per cent of the representative have opined that the product attribute helps to increase sale, 27.8 per cent of them have opined that the promotion attribute helps to increase sales, 12.7 per cent of them have opined that the process attribute helps to increase sales and a least 10.1 per cent of the have opined that the packaging attribute helps to increase sales.



# SELLING PROCESS ADOPTED THE PHARMACEUTICAL COMPANIES

The following table 3 details the selling process adopted the pharmaceutical companies, for the purpose of the analysis factor analysis have been employed.

Table 3: Clustering of variable												
Statements	1	2	3	4	5	6	7	8	Commu nality	Labelled as		
Frequency of sponsoring conference is high	.953		T						.942			
Sponsoring of gifts/ materials is continuous	.827		J.C.	1		<u>.</u>			.761	Sponsorship		
The gifts and the sponsors are in touch with sales	.766		1 ph	<u>~</u>	2				.644			
The brand name ensures Quality		.961	5						.949			
The brand name have fetched confidence		.832				No.			.724	Brand Name		
The brand name certainly stimulated the sale		.805				X			.689			
The brand name is not confusing		.755		X					.651			
Because of advertising the sales has increased			.939		10				.958			
The advertising is made immediately after competing brands			.932	X					.952	Advertisement		
The sales is much better through TV ads on prime shows			.917						.917			
Additional or "Extra", "Free samples" boost sales				.959					.949			
The store ambience increase				.973					.978			

the sale medicine/drugs										
The customers were easily				.970					071	Store
remembering the store name				.970					.971	
I can rely upon the store for				.963					.966	
its Quality				.905					.900	
The store provide all brands		100mm		.929	Contraction of the second s				.903	
of medicine/drugs		N		.929		-			.905	
The company see that the		57								
advertisement is constantly	1	9. A.		1	.967					
telecasted				8	100					
The company does not			Co Stand	and the second	.951	1934-			.947	
change the celebrity often			1.6		.))]				.)+/	Inputs from
The printed Catalogues and			150		-20					the company
bit notices are liked by			200		.981	$\Lambda$ , 1			.983	
customers						34				
The printed Information		A NG	100	k	.971	24			.964	
details the drug and disease			1		.)/1	34	10.		.70+	
The printed catalogues are			2 3		.935		16		.911	
very informative			S.		.755				.711	
Location of the distributor						.969			.968	
makes the sales easier			A		1	.,0)	19		.700	
Gifts and discounts		N. C.	VA.			.961	0		.958	Distributors
increases the sales			10 M	<u> </u>	ALL	.,,01			.750	
The distributors keeps the					die	.943			.907	
product on sale		1		10-50					.907	
Reasonable price hike does				b.,			.979		.988	
not affect the sales			100						.700	
Too many Price deals							.959		.940	Price
Shatters sales										
The prices are kept high							.959		.950	
The competitors distribution								.965	.950	
strategy is noted										
Price deals alters the sales								.929	.892	Sales

The company strongly								.944					
believes in celebrity									.930				
endorsement													
Eigen value	9.355	7.342	4.295	2.112	1.918	1.191	0.721	0.452					
% of variance	26.752	22.956	19.733	9.480	4.041	3.917	3.874	3.681					
Total variance		litera .		94.433	%	-							
КМО				.706									
Approx. Chi-Square	Approx. Chi-Square 21410.223												
Sig000													
Source: Computed from Primary	Data			1 10									

Table 3 details the reliability/KMO and Bartlett's test employed. As the sampling adequacy, value is more than .005 the statement were found for performing further analysis.

The following section details the opinion of the medical representatives on the selling process adopted the pharmaceutical companies for selling process adopted the pharmaceutical companies.

Ho: There is no difference among opinion of the medical representatives with respect to the selling process adopted the pharmaceutical companies

H1: There is a difference among opinion of the medical representatives with respect to the selling process adopted the pharmaceutical companies

	Spons	sorship	Bran	d name	Adver	tisement	St	ore	In	puts	Distri	ibutors	Рі	rice	Sa	ales
Factors	F	Result	F	Result	F	Result	F	Result	F	Result	F	Result	F	Result	F	Result
	value		value		value		value		value	- Aller	value		value		value	
Selling	1.821	S	2 0 2 0	c	2.486	S	1 (50	S	2 420	S	2 (02	C	4.398	C	2.099	C
category	1.821	2	2.030	S	2.480	3	1.650	2	3.430	2	3.693	S	4.398	S	2.099	S
Type of	0.000	C	2.120	2	0 700	NG	0.450	a a	2 2 2 2 7	G	2.212	C	0.001	C	4 070	G
company	2.062	S	3.120	S	0.733	NS	2.450	S	3.227	S	3.312	S	2.331	S	4.373	S
Market	1 700	c	2 777	c	2 250	G	1 0 1 0	NG	0.40	NG	020	NG	002	NG	000	NG
segmentation	1.782	S	3.777	S	2.259	S	1.212	NS	.842	NS	.929	NS	.983	NS	.990	NS
Marketing	000	NG	0.400	C	0 (14	A AS	0.000	NG	020	NG	4 4 4 7	C	2 702	C	2.015	G
strategy	.989	NS	2.422	S	0.614	NS	0.822	NS	.928	NS	4.447	S	3.782	S	3.815	S
Attribute						1.51	1		1							
increasing	.945	NS	0.983	NS	2.061	S	1.780	S	4.334	S	2.212	S	2.880	S	2.436	S
sales									11.11	1	10.					

 Table 4: Opinion of the medical representatives on the selling process adopted the pharmaceutical companies

S – Significant

NS – Non Significant




Table 4 shows the results of the analysis of variance between the opinion of the medical representatives and the intrinsic factors. Firstly, the opinion of the medical representative on the sponsorship is examined. The result shows that the selling category, type of company and market segmentation has significant difference among sponsorship. Followed by the opinion of the medical representatives on the brand name is examined, it shows selling category, type of company, market segmentation and marketing strategy have significant difference among brand name. Thirdly, the opinion of the medical representatives on the advertisement is examined, it shows selling category, market segmentation and attribute increase sales have significant difference among advertisement. Fourthly, the opinion of the medical representatives on the store is examined, it shows selling category, type of company and attribute increase sales have significant difference among store. Next, the opinion of the medical representatives on the inputs from the company is examined, it shows selling category, type of company and attribute increase sales have significant difference among inputs from the company. Followed by, the opinion of the medical representatives on the distributors is examined, it shows selling category, type of company, marketing strategy and attribute increase sales have significant difference among distributors. Next, the opinion of the medical representatives on the price is examined, it shows selling category, type of company, marketing strategy and attribute increase sales have significant difference among price. Lastly, the opinion of the medical representatives on the sales is examined, it shows selling category, type of company, marketing strategy and attribute increase sales have significant difference among sales.

# **Findings of the study**

## Simple frequency

- ♦ Most 58.2 per cent of the medical representative were employed in Coimbatore district.
- ♦ Most 53.9 per cent of the respondents have completed post-graduation.
- A majority 41.8 per cent of the respondents belongs to the age group of 25 35.
- A majority 42.5 per cent of the representatives have 0-5 years of experience.
- ✤ A majority 47.4 per cent respondents were involved in selling pharma products.
- ♦ A majority 35.6 per cent of the medical representative are working for Pfizer.
- Most 47.4 per cent of the pharmaceutical companies adopt demographic segmentation.

- ♦ Most 34.6 per cent of them concentrate on both segment and branded strategies.
- ✤ A majority 49.3 per cent of them opined that the product attribute helps to increase sales

## **Factor analysis**

The selling process adopted the pharmaceutical companies were grouped under eight heads viz.., Sponsorship, Brand Name, Advertisement, Store, Inputs from the company, Distributors, Price and Sales.

#### Anova:

- The opinion of the medical representative on the sponsorship is examined. The result shows that the selling category, type of company and market segmentation have significant difference among sponsorship.
- The opinion of the medical representatives on the brand name is examined, it shows selling category, type of company, market segmentation and marketing strategy have significant difference among brand name.
- The opinion of the medical representatives on the advertisement is examined, it shows selling category, market segmentation and attribute increase sales have significant difference among advertisement.
- The opinion of the medical representatives on the store is examined, it shows selling category, type of company and attribute increase sales have significant difference among store.
- The opinion of the medical representatives on the inputs from the company is examined, it shows selling category, type of company and attribute increase sales have significant difference among inputs from the company.
- The opinion of the medical representatives on the distributors is examined, it shows selling category, type of company, marketing strategy and attribute increase sales have significant difference among distributors.
- The opinion of the medical representatives on the price is examined, it shows selling category, type of company, marketing strategy and attribute increase sales have significant difference among price.

The opinion of the medical representatives on the sales is examined, it shows selling category, type of company, marketing strategy and attribute increase sales have significant difference among sales.

## Conclusion

It would be truly unrealistic for every single Medical representative to challenge the marketing activities adopted by the pharmaceutical companies with more profundity of learning and science; however legitimate preparing and arrangement will help convey right and required data about medications to specialists. Further, it would be increasingly powerful if the medical representatives can persuade specialist through solid and convincing relational abilities. In contrast to other limited time devices, deals delegates have choice to talk about and demonstrate their focuses, for example, why their medications are increasingly powerful and what treatment conditions they fit, all the more explicitly. The attention on improving the nature of gatherings between therapeutic delegates' and Doctors can be viable to improve the present picture of medicinal agent's from "undesirable deals visits too progressively proficient/drawing in session" along these lines advancing brand adequately.

## Reference

- Jaya Prakash Pradhan. Institute for Studies in Industrial Development, 2006. Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies 2008.
- Elizabeth Murray, Rodney McAdam, Moira T. Burke. A critique of emerging European legislation in the pharmaceutical industry: a clinical trials analysis. International Journal of Health Care Quality Assurance 2004; Volume: 17 Issue: 7.
- \* Chris Cousins. Pharmaceutical Marketing: The Unethical Reform of an Industry